CL2014003391A1 - Compuestos de azetidina y piperidina; metodo de preparacion; composicion farmaceutica; y uso para tratar un trastorno cognitivo mediado por pde10. - Google Patents

Compuestos de azetidina y piperidina; metodo de preparacion; composicion farmaceutica; y uso para tratar un trastorno cognitivo mediado por pde10.

Info

Publication number
CL2014003391A1
CL2014003391A1 CL2014003391A CL2014003391A CL2014003391A1 CL 2014003391 A1 CL2014003391 A1 CL 2014003391A1 CL 2014003391 A CL2014003391 A CL 2014003391A CL 2014003391 A CL2014003391 A CL 2014003391A CL 2014003391 A1 CL2014003391 A1 CL 2014003391A1
Authority
CL
Chile
Prior art keywords
pde10
azetidine
treat
preparation
pharmaceutical composition
Prior art date
Application number
CL2014003391A
Other languages
English (en)
Spanish (es)
Inventor
Jian J Chen
Michael J Frohn
Jennifer R Allen
Robert M Rzasa
Wenge Zhong
Alexander J Pickrell
Thomas T Nguyen
Matthew Richard Kaller
Quingyian Liu
Wenyuan Qian
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48692687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003391(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2014003391A1 publication Critical patent/CL2014003391A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
CL2014003391A 2012-06-14 2014-12-12 Compuestos de azetidina y piperidina; metodo de preparacion; composicion farmaceutica; y uso para tratar un trastorno cognitivo mediado por pde10. CL2014003391A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261659911P 2012-06-14 2012-06-14

Publications (1)

Publication Number Publication Date
CL2014003391A1 true CL2014003391A1 (es) 2015-07-10

Family

ID=48692687

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003391A CL2014003391A1 (es) 2012-06-14 2014-12-12 Compuestos de azetidina y piperidina; metodo de preparacion; composicion farmaceutica; y uso para tratar un trastorno cognitivo mediado por pde10.

Country Status (25)

Country Link
US (3) US8691986B2 (cg-RX-API-DMAC10.html)
EP (1) EP2864317A1 (cg-RX-API-DMAC10.html)
JP (1) JP2015519402A (cg-RX-API-DMAC10.html)
KR (1) KR20150023417A (cg-RX-API-DMAC10.html)
CN (1) CN104619694A (cg-RX-API-DMAC10.html)
AP (1) AP2014008136A0 (cg-RX-API-DMAC10.html)
AR (1) AR091436A1 (cg-RX-API-DMAC10.html)
AU (1) AU2013274153B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014031368A2 (cg-RX-API-DMAC10.html)
CA (1) CA2875802A1 (cg-RX-API-DMAC10.html)
CL (1) CL2014003391A1 (cg-RX-API-DMAC10.html)
CO (1) CO7160011A2 (cg-RX-API-DMAC10.html)
CR (1) CR20150012A (cg-RX-API-DMAC10.html)
EA (1) EA201590014A1 (cg-RX-API-DMAC10.html)
HK (1) HK1203935A1 (cg-RX-API-DMAC10.html)
IL (1) IL235901A0 (cg-RX-API-DMAC10.html)
MA (1) MA37748B1 (cg-RX-API-DMAC10.html)
MX (1) MX2014014924A (cg-RX-API-DMAC10.html)
PE (1) PE20150348A1 (cg-RX-API-DMAC10.html)
PH (1) PH12014502780A1 (cg-RX-API-DMAC10.html)
SG (1) SG11201408168UA (cg-RX-API-DMAC10.html)
TN (1) TN2014000510A1 (cg-RX-API-DMAC10.html)
TW (1) TWI508959B (cg-RX-API-DMAC10.html)
UY (1) UY34858A (cg-RX-API-DMAC10.html)
WO (1) WO2013188724A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103221404B (zh) 2010-05-13 2015-12-16 安姆根有限公司 可用作pde10抑制剂的不饱和氮杂环化合物
AR091436A1 (es) * 2012-06-14 2015-02-04 Amgen Inc Compuestos de azetidina y piperidina utiles como inhibidores de pde10

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CN103221404B (zh) 2010-05-13 2015-12-16 安姆根有限公司 可用作pde10抑制剂的不饱和氮杂环化合物
CA2800578A1 (en) * 2010-05-13 2011-11-17 Amgen Inc. Nitrogen-heterocyclic compounds as phosphodiesterase 10 inhibitors
EP2569302A1 (en) * 2010-05-13 2013-03-20 Amgen, Inc Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
US8952037B2 (en) * 2010-05-13 2015-02-10 Amgen Inc. Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
AR091436A1 (es) * 2012-06-14 2015-02-04 Amgen Inc Compuestos de azetidina y piperidina utiles como inhibidores de pde10

Also Published As

Publication number Publication date
AU2013274153A1 (en) 2014-12-18
EA201590014A1 (ru) 2015-04-30
JP2015519402A (ja) 2015-07-09
WO2013188724A1 (en) 2013-12-19
MA37748A1 (fr) 2016-11-30
HK1203935A1 (en) 2015-11-06
US20140148435A1 (en) 2014-05-29
MX2014014924A (es) 2015-03-09
CO7160011A2 (es) 2015-01-15
TN2014000510A1 (en) 2016-03-30
TW201412729A (zh) 2014-04-01
US8691986B2 (en) 2014-04-08
US9303028B2 (en) 2016-04-05
PE20150348A1 (es) 2015-03-04
PH12014502780A1 (en) 2015-02-02
UY34858A (es) 2013-11-29
CR20150012A (es) 2015-02-11
US20130338138A1 (en) 2013-12-19
AR091436A1 (es) 2015-02-04
MA37748B1 (fr) 2017-07-31
AP2014008136A0 (en) 2014-12-31
BR112014031368A2 (pt) 2017-06-27
US9493459B2 (en) 2016-11-15
AU2013274153B2 (en) 2016-05-19
SG11201408168UA (en) 2015-01-29
IL235901A0 (en) 2015-09-24
KR20150023417A (ko) 2015-03-05
CA2875802A1 (en) 2013-12-19
CN104619694A (zh) 2015-05-13
EP2864317A1 (en) 2015-04-29
TWI508959B (zh) 2015-11-21
US20160176874A1 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
EP2869371A4 (en) POSITIVE ELECTRODE MIXTURE
GB2535435B (en) Methods for treating lignocellulosic materials
DK2934836T3 (da) Splitting apparatus
DK3181128T3 (da) Farmaceutisk nilotinib-sammensætning
CL2014003386A1 (es) Métodos y composiciones para producción de biometano
DK2914965T3 (da) Aflukker til biologiske mikroobjekter
DK2694038T3 (da) Farmaceutisk sammensætning
BR112015002738A2 (pt) composto , e , composição farmacêutica
PT2729151T (pt) Composição farmacêutica, métodos de tratamento e suas utilizações
DK3360538T3 (da) Injicerbar, flydende sammensætning omfattende buprenorphin
LT2861223T (lt) Kompozicijos ir būdai, skirti absorbavimui per gleivinę
EP2914335A4 (en) COMPOSITIONS, STRUCTURES AND METHODS OF NERVE REGENERATION
ZA201501930B (en) Pharmaceutical composition
BR112014009889A2 (pt) compostos dissubstituídos, compostos e composição farmacêutica
IL237914A0 (en) Benzamides
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
DK2897594T3 (da) Farmaceutisk sammensætning
BR112014031899A8 (pt) composto, composição farmacêutica, e, método para tratamento de um distúrbio
BR112015008113A2 (pt) novo processo para preparar compostos para uso no tratamento de câncer.
IL266415A (en) Innovative pharmaceutical composition
BR112015010797A2 (pt) compostos aniônicos substituídos, e, composição farmacêutica
FR2990940B1 (fr) Melange refractaire non faconne.
BR112014029665A2 (pt) composição absorvedora
BR112013022930A2 (pt) composição farmacêutica, uso de uma composição farmacêutica, e, processo para produzir uma composição farmacêutica
EP2891483A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTRO-SOPHAGEAL REFLUX PATHOLOGICAL